The Empty Chair in the Factory
There is now rare agreement across the continent that Africa must make its own medical supplies. Presidents, regional disease-control bodies, and the African Medicines Agency share one view: depending on supply chains controlled by others is a danger the continent will no longer accept. That view is right. But its execution leaves out the same thing in every plan, so consistently that it can no longer be read as an accident. Contraceptives and other sexual and other reproductive health products have no seat at the table where Africa’s health-manufacturing future is being designed. As things stand, the drive for independence will reproduce, inside African institutions and by African hands, the exact narrowing of reproductive health that the continent resists when it comes from Washington. A country that does not make the products women depend on is not independent. It has simply moved its dependence to a more flattering address.
The Contradiction at the Heart of Africa’s Health Independence
What Africa has built in the eighteen months to mid-2026 is formidable. The Africa Health Strategy and Systems Agenda became the core framework for health funding, the workforce, community health, and local manufacturing at the 39th African Union Summit1. The African Medicines Agency brought continent-wide regulation under one roof through a cooperation agreement with the World Health Organization, signed alongside the 79th World Health Assembly, committing both sides to aligned rules, shared work, mutual recognition of approvals, and a three-to-five-year plan covering product approval and local production2. The AU’s special summit on health manufacturing met in Nairobi under a target of making at least sixty per cent of the continent’s vaccines in Africa by 20403. Kenya’s progress toward WHO Maturity Level 3 for medicines regulation, advanced at the World Health Summit Regional Meeting in Nairobi, sets the regulatory standard a country needs before it can make these products at home4. Each is a real instrument of control.
The deep flaw lies in the thinking that decided which products all this was built to protect. The whole system is geared to the rare and the dramatic: pandemic pathogens, vaccines, biosecurity threats, and the emergencies that mobilise political attention and donor money. It is built for the exceptional crisis, not for the everyday and the recurrent. The day-to-day safety of a woman who needs a contraceptive implant, a medicine to stop heavy bleeding after childbirth, or magnesium sulphate to manage eclampsia falls entirely outside the manufacturing plan the sixty-per-cent goal governs5. A May 2026 review of the Nairobi decisions stated the result plainly: contraceptive manufacturing is absent from the continent’s production roadmaps, and almost all modern contraceptives used across sub-Saharan Africa are imported, a weakness laid bare during the COVID-19 supply breakdown and again when the Strait of Hormuz closed6.
This bias feeds on itself through the path procurement takes once it starts. As soon as the African Pooled Procurement Mechanism and the African Medicines Agency’s approval plan fix their first product list around pandemic and infectious-disease supplies, everything that follows inherits it: every later investment decision, every manufacturer’s plan for where to put its capital, and every regulatory application treats that starting list as settled. Reproductive health products are being deferred, and deferral while the system is still being designed hardens quietly into permanent exclusion, long before any minister is asked to vote on it. The institutional connections that could correct this already exist. For example, the UNFPA–Africa CDC partnership signed at the February 2026 AU Summit targets exactly this: jointly buying reproductive, maternal, newborn, and adolescent health products, scaling innovation, and combining public and private money7. The problem is that the mandate has not been written into the product lists where manufacturing decisions are actually made.
The Outside Pressures and Money Risks
The case for making reproductive health products in Africa rests not on hope but on how clearly the alternative has just failed. The continent has seen in plain sight what happens when the basic security of women’s health depends on a single foreign government in a divided and volatile world. How the damage spreads is no longer theory.
The first pressure is policy. The shift in United States engagement under the America First approach, presented as a move away from aid, dependency, and what it calls divisive ideology, removed sexual and reproductive health from American assistance by design. The expanded Mexico City Policy, renamed Promoting Human Flourishing in Foreign Assistance, attached its conditions to all non-military United States foreign aid, around thirty billion dollars a year, roughly fifty times the reach of the original rule8, and the wider cuts to aid forced family planning clinics across the continent to close9. Independent analysis found that about ninety-four per cent of United States funding for sexual and reproductive health was cut, a withdrawal equal to more than one hundred and thirty thousand women losing access to contraception each day10. A single political shift in one Western capital squeezed the funding for an entire area of health across a whole continent. That is the precise shape of a risk that cannot be spread or hedged, and prudent institutions do not leave something so basic exposed to it.
The second pressure is financial and comes from outside Africa. The closure of the Strait of Hormuz during the conflict of February to March 2026, a route carrying about a fifth of the world’s oil, drove a price spike that fell hardest on oil-importing African economies11. The resulting inflation compresses national health budgets, and within them reproductive health is classed as non-emergency spending and cut first under austerity. The same conflict disrupted the shipping routes that imported contraceptives depend on. So, a geopolitical event with no obvious link to reproductive health degraded both the money to buy these products and the supply chain to deliver them at once, through two entirely separate channels.
The third pressure is the false comfort of what is replacing the old aid. The funding now consolidating around the continent does not restore the lost grants; it substitutes tools poorly suited to delivering reproductive health. The bilateral health agreements signed with thirty-one governments, covering spending to 2030 and worth at least twenty billion dollars, roughly thirty-seven per cent of it to be paid by the receiving countries themselves, steer support away from family planning, maternal health, and children’s health toward a narrower focus on health security12. The now-fashionable reliance on private money and blended finance depends on commercial returns, and there are few if any to be had from a service whose users are mostly the poorest women and adolescents. That is why health captures only a tiny share of global blended-finance flows, and reproductive health a smaller share still13.
Africa is being asked to treat as permanent infrastructure a set of funding tools that are plainly conditional, contingent, and procyclical: each shrinks at exactly the moment need rises. The record forces a structural conclusion: no external instrument on offer today can sustainably fund a steady supply of reproductive health products, because every one of them is governed by political or commercial logic. Making these products at home is not the best option among several. It is the only one that removes the dependence on the very channels that have just failed.
Bringing Manufacturing Policy and Health Fairness Together
The argument below is framed deliberately outside the language of charity or welfare. Making reproductive health products at home is presented here as an economic and national-security imperative, on the same footing as making vaccines, because that is what the economic and geopolitical evidence shows it to be. A country that cannot secure its own supply of the products needed to keep women alive through childbirth and to manage its demographic transition has a sovereignty gap of the first order, however the issue is usually labelled.
- Decide now which products will be made: The single highest-leverage step is to name reproductive health products explicitly on the African Medicines Agency’s approval plan and the African Pooled Procurement Mechanism’s buying list, before those lists harden. The AMA–WHO cooperation agreement and the support programme for small and medium manufacturers launched alongside it give Africa the means14. What is required is the deliberate inclusion of contraceptives, the medicines used to manage childbirth, and post-abortion-care products on the early list, framed as continental supply security. The foreign aid that once paid for the regulation and quality assurance behind family planning supplies is now gone, which makes the shared continental system its only credible successor.
- Make the money case in the language funders use: The investment case must be made in the language the funders already speak. The economic argument is direct and measurable: contraceptive access means more women in work, fewer maternal deaths and so households kept productive, and a managed demographic transition that underpins long-term growth, with every dollar in family planning and maternal health returning several in economic benefit15. This framing fits the investment language of the Nairobi Declaration adopted at the Africa Forward Summit and the sustainable-finance pillar that France carries as G7 host toward Evian16 and are concrete, ready-made homes into which reproductive health manufacturing can be inserted as an investment worth backing.
- Use shared rules as a shield: Consolidating continent-wide regulation under the African Medicines Agency and moving medicines regulation over from the earlier regional body, creates a single point of leverage that did not exist before. One shared approval standard for reproductive health products lets African manufacturers reach many national markets at once, converting a scattered set of national hurdles into a single continental market. This is how rule alignment, usually treated as a dry technical task, becomes the decisive instrument of health independence. It is also how the continent insulates itself from the conditions buried in bilateral deals, because a product made, approved, and bought entirely within Africa’s own system is beyond the reach of any gag rule imposed from outside.
- Act in the right order before the window closes: The calendar of meetings offers a finite set of decision points, and the cost of inaction compounds at each one. The AU mid-year coordination meeting, the 76th WHO Regional Committee for Africa in Addis Ababa, and the maturing of the UNFPA–Africa CDC partnership through the second half of 2026 are the nearest moments at which the product list can still be amended17. The WHO reforms reporting to the 80th World Health Assembly, the United Kingdom’s G20 presidency, and the African manufacturing build-out all mature within the same eighteen-month corridor. The operative point is irreversibility: if the manufacturing scope, regulatory baselines, and buying lists are set now without reproductive health products, a later change of political weather in a donor capital will not reopen them, because committed factories and approvals do not reverse within one electoral cycle. This decision is being made during this window whether or not anyone makes it deliberately.
The empty chair in the factory is not yet bolted to the floor. For a short and shrinking window, it remains a chair that Africa’s own institutions can choose to fill. The structure of health independence is being poured around it like concrete. The only question that matters is whether reproductive health products are written into the plan while the concrete is still wet, or whether the continent discovers, after it has set hard, that it manufactured its own independence and left the basic security of half its people standing outside the building.
